Search
Close
Search
Advanced Search
Search Menu
AI Research Assistant

Abstract

Objective: To evaluate the efficacy and tolerability of doxazosin (DOX) as add-on therapy in male patients with hypertension inadequately controlled by 1 or 2 other antihypertensive medications.

Methods: A subanalysis from HABIT evaluated DOX in men whose blood pressure (BP) was inadequately controlled (systolic BP [SBP] of 140–179 mm Hg and diastolic BP [DBP] of 90–109 mm Hg) with 1 or 2 antihypertensive agents (excluding α1-blockers). During the dose titration phase (≤5 weeks), the initial daily dose of DOX 1 mg could be increased weekly to a maximum of 16 mg as needed to control BP without unacceptable adverse events. The optimal dose was continued for 8 weeks in the maintenance phase.

Results: In 117 patients with treated/poorly controlled BP at baseline, 8 weeks of DOX add-on therapy reduced sitting DBP and SBP by 11 mm Hg and 14 mm Hg, respectively. In 22 patients receiving an angiotensin-converting enzyme inhibitor (ACE-I), the addition of DOX produced mean reductions in DBP and SBP of 14 mm Hg and 15 mm Hg, respectively. In 36 patients receiving a calcium channel blocker (CCB), the addition of DOX produced mean reductions in DBP and SBP of 10 mm Hg and 11 mm Hg, respectively. And in 39 patients receiving combinations of any 2 other classes of antihypertensive drugs, the addition of DOX resulted in marked mean reductions in DBP and SBP of 12 mm Hg and 16 mm Hg, respectively. The proportion of patients on each regimen who achieved DBP <90 mm Hg and SBP <140 mm Hg after the addition of DOX was as follows: ACE-I 73%, CCB 42%, and a combination of any two classes 56%. Furthermore, DOX was well tolerated. The most commonly reported treatment-related adverse events were dizziness (13% of patients; mild in most cases), fatigue (4.3%), somnolence (3.2%), and headache (2.4%).

Conclusion: The results seen in this subset of patients from HABIT demonstrate that DOX is effective as add-on therapy for patients whose hypertension is poorly controlled with 1 or 2 other antihypertensive medications. DOX is also well tolerated. Grant/Research Support: Bristol Myers Squibb, AstraZeneca, Solvay Consultant: Bayer, AstraZeneca.

Speaker's Bureau: Bayer, SmithKline, Bristol Myers Squibb, Solvay Other Financial or Material Support: Pfizer, Inc.

Hypertension, Doxazosin, Blood pressure
This content is only available as a PDF.
© American Journal of Hypertension, Ltd. 2001
Topic:
Issue Section:
Abstracts
You do not currently have access to this article.
Download all slides